Procter and Gamble has raised its dividend every year for seven decades, and it is not even the highest-yielding name on this list. These five household giants reveal just how differently income…
Pfizer's yield towers over Johnson and Johnson's, but a bigger number on paper can hide serious risks underneath. Before you chase that payout, consider what a frozen dividend, rising debt, and a…
Johnson & Johnson just logged its 64th straight year of dividend growth, but biosimilar threats, a MedTech slowdown, and lingering talc litigation raise a real question about whether that streak justifies buying…
Market indicators are flashing red heading into October, and investors who wait too long to reposition may regret it. Five elite dividend stocks in healthcare, consumer staples, and utilities have weathered every…
Dave Ramsey and Suze Orman have built careers on helping people retire with dignity, yet on one of the most consequential investment decisions a retiree faces, they point in completely opposite directions.…
Yield alone tells you nothing about whether a dividend actually survives a recession or a patent cliff. These five stocks have built long streaks of consecutive raises from businesses that look nothing…
Both Dividend Kings trade at nearly identical valuations, so the real question becomes which one can actually keep raising its payout for two decades without flinching. The answer comes down to three…
Your tax bracket quietly decides whether muni bonds or dividend stocks put more cash in your pocket, and most retirees are running the comparison wrong from the start.
A gas station attendant and part-time janitor from Vermont quietly accumulated over 95 stocks across five decades, and what his neighbors discovered after his death in 2014 stunned an entire community.
Dave Ramsey has called single stocks a gamble for years, but retirees who pay their bills with dividends from stocks like Johnson and Johnson are making a very different bet. Whether his…
Chris Lange Both JNJ and MRK have surged in 2026, but a looming patent cliff and a balance sheet loaded with acquisition debt mean one of these pharma dividends faces a reckoning that retirement…
With the 10-year Treasury now paying more than most income stocks, five dividend names face a simple question: does real cash actually back the payout, or just the yield number on the…
Bank of America just raised price targets on two pharma giants facing patent cliffs, but its conviction level differs sharply between them, and the valuation gap may explain which one belongs in…
Amgen just handed income investors another dividend raise, but a mountain of acquisition debt, crumbling legacy drugs, and a billion-dollar obesity bet are all competing for the same pool of cash.
Three stocks have raised their dividends for over 30 consecutive years through recessions, wars, and market crashes, and one has paid shareholders without interruption for 136 years straight. Find out which name…
